Hologic INC (HOLX) — SEC Filings

Overview

Hologic INC (HOLX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S filed on Apr 7, 2026: Hologic Inc. filed an S-8 POS form on April 7, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing is a post-effective amendment, indicating updates or additions to previously registered securities for employee compensation. The company's

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant filing sentiment for Hologic INC is neutral.

Filing Type Overview

Hologic INC (HOLX) has filed 2 EFFECT, 17 S, 20 8-K, 2 10-K, 3 DEFA14A, 4 10-Q, 1 DEF 14A, 1 SC 13G/A with the SEC between Jul 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• EFFECT Filing — EFFECT · Apr 13, 2026
• EFFECT Filing — EFFECT · Apr 13, 2026
• S Filing — S · Apr 7, 2026
• Hologic Inc. Files S-8 POS for Employee Stock Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing
• S Filing — S · Apr 7, 2026
• Hologic Inc. Files S-8 POS for Employee Benefit Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing
• S Filing — S · Apr 7, 2026
• Hologic Inc. Files S-8 POS for Employee Benefit Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, related to securities to be offered to employees in employee benefit plans. This filing is a post-effective
• Hologic Inc. Files S-8 POS for Employee Benefit Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, to register an unspecified number of securities to be offered under its employee benefit plans. This filing
• S Filing — S · Apr 7, 2026
• S Filing — S · Apr 7, 2026
• Hologic Inc. Files S-8 POS for Employee Benefit Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing
• S Filing — S · Apr 7, 2026
• Hologic Inc. Files S-8 POS for Employee Benefit Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing
• Hologic Inc. Files S-8 POS for Employee Benefit Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing
• S Filing — S · Apr 7, 2026
• Hologic Inc. Files S-8 POS for Employee Benefit Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing
• S Filing — S · Apr 7, 2026
• Hologic Inc. Files S-8 POS for Employee Benefit Plans — S · Apr 7, 2026 Risk: low
  Hologic Inc. filed an S-8 POS form on April 7, 2026, registering an unspecified number of securities to be offered under its employee benefit plans. This filing
• 8-K Filing — 8-K · Apr 7, 2026
• Hologic Inc. Files 8-K: Officer/Director Changes & Financials — 8-K · Apr 6, 2026 Risk: medium
  Hologic Inc. announced on April 6, 2026, changes related to its officers and directors, as well as other events and financial statements. The filing details Ite
• Hologic to Go Private in $79/Share Deal with Blackstone, TPG — 10-K · Nov 18, 2025 Risk: medium
  Hologic, Inc. (HOLX) reported a definitive agreement on October 21, 2025, to be acquired by funds managed by Blackstone Inc. and TPG Capital for $76.00 per shar
• DEFA14A Filing — DEFA14A · Nov 10, 2025
• 8-K Filing — 8-K · Nov 7, 2025
• Hologic to be Acquired by Blackstone and TPG — DEFA14A · Nov 5, 2025 Risk: medium
  Hologic, Inc. announced on November 5, 2025, that it is being acquired by Blackstone and TPG. This announcement was made via an internal FAQ distributed to empl
• 8-K Filing — 8-K · Nov 3, 2025
• Hologic CEO Video Shared Internally — DEFA14A · Oct 28, 2025 Risk: low
  On October 28, 2025, Hologic, Inc. (Hologic) filed a DEFA14A, indicating it released an internal video to employees. The video featured Stephen MacMillan, Holog
• Hologic Inc. Files 8-K: Material Agreements, Officer Changes — 8-K · Oct 21, 2025 Risk: medium
  On October 21, 2025, Hologic, Inc. filed an 8-K report detailing several key events. These include the entry into a material definitive agreement, the departure
• Hologic Announces Board and Executive Compensation Changes — 8-K · Sep 19, 2025 Risk: low
  Hologic, Inc. announced on September 18, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depa
• 10-Q Filing — 10-Q · Jul 31, 2025
• Hologic Inc. Files 8-K on Financials — 8-K · Jul 30, 2025 Risk: low
  Hologic, Inc. filed an 8-K on July 30, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and e
• Hologic Inc. Enters Material Definitive Agreement — 8-K · Jul 18, 2025 Risk: medium
  On July 15, 2025, Hologic, Inc. entered into a material definitive agreement, likely related to a financial obligation. The company, incorporated in Delaware, f
• Hologic Inc. Files 10-Q for Q2 2025 — 10-Q · May 2, 2025 Risk: low
  Hologic Inc. filed its 10-Q for the period ending March 29, 2025. The company's fiscal year ends on September 28. Key financial data for the quarter and year-to
• Hologic, Inc. Files 8-K on Financials — 8-K · May 1, 2025 Risk: low
  Hologic, Inc. filed an 8-K on May 1, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The fil
• Hologic, Inc. Files 8-K: Director/Officer Changes & Financials — 8-K · Apr 4, 2025 Risk: medium
  Hologic, Inc. filed an 8-K on April 4, 2025, reporting changes related to its directors and officers, including potential departures, elections, and compensator
• Hologic, Inc. Reports Director/Officer Changes and Compensation — 8-K · Mar 3, 2025 Risk: medium
  Hologic, Inc. filed an 8-K on March 3, 2025, reporting events as of February 26, 2025. The filing primarily concerns the departure of directors or certain offic
• Hologic Reports on Shareholder Votes — 8-K · Feb 28, 2025 Risk: low
  Hologic, Inc. filed an 8-K on February 28, 2025, reporting on matters submitted to a vote of its security holders on February 26, 2025. The filing details the o
• Hologic Q1 Revenue Dips Slightly to $914.5M — 10-Q · Feb 6, 2025 Risk: medium
  Hologic Inc. reported its financial results for the first quarter of fiscal year 2025, ending December 28, 2024. The company's revenue for the quarter was $914.
• Hologic Inc. Files 8-K on Financials — 8-K · Feb 5, 2025 Risk: low
  Hologic, Inc. filed an 8-K on February 5, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. Th
• Hologic Inc. Files 2025 Proxy Statement — DEF 14A · Jan 16, 2025 Risk: low
  Hologic Inc. filed its DEF 14A proxy statement on January 16, 2025, for its fiscal year ending September 28, 2025. The filing provides details regarding the com
• Hologic Inc. Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
  Hologic, Inc. filed an 8-K on January 13, 2025, reporting on its Results of Operations and Financial Condition as of January 12, 2025. The filing includes finan
• Hologic Appoints New Chief Accounting Officer and General Counsel — 8-K · Jan 10, 2025 Risk: low
  Hologic, Inc. announced on January 6, 2025, changes in its executive team. The company appointed Robert L. Johnson as Chief Accounting Officer and Senior Vice P
• Hologic CFO Departs; Interim CFO Appointed — 8-K · Dec 9, 2024 Risk: medium
  Hologic, Inc. announced on December 6, 2024, the departure of its Chief Financial Officer, Michael J. Watts, effective December 13, 2024. The company has appoin
• Hologic Inc. Files 2024 10-K Report — 10-K · Nov 27, 2024 Risk: medium
  Hologic Inc. filed its 10-K for the fiscal year ending September 28, 2024, reporting on its financial performance and business operations. The company, headquar
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Hologic CFO Departs; Interim Appointed; Q4 Revenue $1.07B — 8-K · Nov 8, 2024 Risk: medium
  Hologic Inc. announced on November 5, 2024, the departure of its Chief Financial Officer, Michael J. Watts, effective November 8, 2024. The company has appointe
• Hologic Inc. Files 8-K on Financials — 8-K · Nov 4, 2024 Risk: low
  Hologic, Inc. filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. Th
• Hologic Sells Interventional Radiology Business to Philips for $225M — 8-K · Sep 13, 2024 Risk: medium
  Hologic, Inc. announced on September 12, 2024, that it has entered into a definitive agreement to sell its Interventional Radiology (IR) business to Royal Phili
• Hologic Inc. Files 10-Q for Q3 2024 — 10-Q · Jul 30, 2024 Risk: medium
  Hologic Inc. reported its third-quarter results for the period ending June 29, 2024. The company's filing indicates financial performance and operational detail
• Hologic Inc. Files 8-K on Financials — 8-K · Jul 29, 2024 Risk: low
  Hologic, Inc. filed an 8-K on July 29, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits

Risk Profile

Risk Assessment: Of HOLX's 34 recent filings, 0 were flagged as high-risk, 13 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Stephen MacMillan
• Robert L. Johnson
• Kevin J. Ryan
• Michael J. Watts

Industry Context

Hologic operates in the highly competitive medical technology sector, focusing on women's health and well-being. Key areas include diagnostics (molecular, cytology), medical imaging (mammography), and surgical products. The industry is characterized by rapid technological advancements, stringent regulatory oversight, and a growing emphasis on early disease detection and minimally invasive treatments. Consolidation through M&A is common, driven by the need for scale, R&D investment, and market access.

Top Tags

employee-benefits (9) · financials (6) · financial-reporting (6) · registration-statement (4) · sec-filing (4) · stock-plan (4) · corporate-governance (4) · 8-k (4) · registration (2) · securities-registration (2)

Key Numbers

• Filing Date: 2026-04-07 — Date of S-8 POS filing
• Cash per share: $76.00 — Base acquisition price for Hologic shares
• Contingent Value Right (CVR): $3.00 — Potential additional cash per share, non-tradable
• Total potential consideration: $79.00 — Maximum per-share value for Hologic stockholders in the acquisition
• Market Value (non-affiliate): $13.57B — Aggregate market value of non-affiliate common stock as of March 29, 2025
• Shares Outstanding: 222.9M — Total common stock shares outstanding as of November 13, 2025
• Reporting Period End Date: 2025-03-29 — Indicates the end of the fiscal quarter being reported.
• Balance Sheet Date: 2023-09-30 — Represents the date for which the company's assets, liabilities, and equity are reported.
• Fiscal Year End: 0928 — Indicates the end of Hologic's fiscal year for financial reporting.
• Revenue: $914.5M — First quarter fiscal year 2025 revenue
• Net Income: $151.1M — First quarter fiscal year 2025 net income
• Prior Year Revenue: $917.8M — First quarter fiscal year 2024 revenue for comparison
• Conformed Period of Report: 20250226 — The period this filing pertains to.
• Fiscal Year Start: 2023-10-01 — The report covers the period starting from this date.
• Q4 Revenue: $1.07B — Indicates recent sales performance

Related Companies

BX · TPG · PHG

Frequently Asked Questions